• Simulations Plus will build the agentic layer of its Composer drug-development platform using NVIDIA’s BioNeMo Agent Toolkit.
• Work extends a May 2026 collaboration on GPU-accelerated simulation, shifting the partnership toward agent-driven modeling workflows.
• Initial focus includes literature-grounded reasoning with Nemotron Parse, aiming to keep outputs traceable to original sources.
• Partners will also advance nvQSP, a CUDA-optimized ODE-solver effort designed to speed quantitative systems pharmacology simulations at scale.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Simulations Plus Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202606230915BIZWIRE_USPR_____20260623_BW040671) on June 23, 2026, and is solely responsible for the information contained therein.